AR044599A1 - METHOD FOR REDUCING THE HARMFUL EFFECTS OF NICOTINE ADMINISTERED BY ORAL OR TRANSDERMAL - Google Patents

METHOD FOR REDUCING THE HARMFUL EFFECTS OF NICOTINE ADMINISTERED BY ORAL OR TRANSDERMAL

Info

Publication number
AR044599A1
AR044599A1 ARP040101917A ARP040101917A AR044599A1 AR 044599 A1 AR044599 A1 AR 044599A1 AR P040101917 A ARP040101917 A AR P040101917A AR P040101917 A ARP040101917 A AR P040101917A AR 044599 A1 AR044599 A1 AR 044599A1
Authority
AR
Argentina
Prior art keywords
tobacco
nicotine
reducing
transdermal
oral
Prior art date
Application number
ARP040101917A
Other languages
Spanish (es)
Inventor
Mark Conkling
Original Assignee
Vector Tobacco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vector Tobacco Ltd filed Critical Vector Tobacco Ltd
Publication of AR044599A1 publication Critical patent/AR044599A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/20—Biochemical treatment
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A24B15/243—Nicotine
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A24B15/245—Nitrosamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

Reducción de los efectos perniciosos de la nicotina administrada por vía oral o transdérmica en programas convencionales para abandonar el uso del tabaco. Más específicamente, las realizaciones se relacionan con métodos para reducir los efectos perniciosos de la ingesta de nicotina asociada con los programas convencionales para abandonar el uso del tabaco, donde se administran productos basados en tabaco que contienen una cantidad reducida de nicotina y nitrosaminas específicas de tabaco (TSNA). Reivindicación 1: Un método para preparar un tabaco mixto con un bajo contenido de nicotina caracterizado porque comprende: proporcionar un primer tabaco, proporcionar un segundo tabaco producido a partir de una planta de tabaco modificada genéticamente que presenta un nivel reducido de QPTasa, en comparación con una planta de tabaco no modificada de la misma variedad, y combinar el primer y el segundo tabaco para obtener dicho tabaco con un contenido de nicotina reducido.Reduction of the pernicious effects of nicotine administered orally or transdermally in conventional programs to quit tobacco use. More specifically, the embodiments relate to methods for reducing the pernicious effects of nicotine intake associated with conventional tobacco cessation programs, where tobacco-based products containing a reduced amount of nicotine and tobacco-specific nitrosamines are administered. (TSNA). Claim 1: A method for preparing a mixed tobacco with a low nicotine content characterized in that it comprises: providing a first tobacco, providing a second tobacco produced from a genetically modified tobacco plant having a reduced level of QPTase, as compared to an unmodified tobacco plant of the same variety, and combining the first and second tobacco to obtain said tobacco with a reduced nicotine content.

ARP040101917A 2003-06-04 2004-06-03 METHOD FOR REDUCING THE HARMFUL EFFECTS OF NICOTINE ADMINISTERED BY ORAL OR TRANSDERMAL AR044599A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47594503P 2003-06-04 2003-06-04

Publications (1)

Publication Number Publication Date
AR044599A1 true AR044599A1 (en) 2005-09-21

Family

ID=33551567

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101917A AR044599A1 (en) 2003-06-04 2004-06-03 METHOD FOR REDUCING THE HARMFUL EFFECTS OF NICOTINE ADMINISTERED BY ORAL OR TRANSDERMAL

Country Status (10)

Country Link
US (1) US20060237025A1 (en)
EP (1) EP1628681A4 (en)
JP (1) JP2007528204A (en)
KR (1) KR20060032141A (en)
CN (1) CN1812811A (en)
AR (1) AR044599A1 (en)
AU (1) AU2004251635A1 (en)
CA (1) CA2527648A1 (en)
WO (1) WO2005000352A1 (en)
ZA (1) ZA200510170B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006247739A1 (en) 2005-05-11 2006-11-23 Vector Tobacco Inc. Reduced risk tobacco products and methods of making same
AR066792A1 (en) * 2007-06-01 2009-09-09 Syngenta Participations Ag METHOD FOR COMMERCIAL PRODUCTION OF TRANSGENIC PLANTS
US7667106B2 (en) * 2007-11-06 2010-02-23 Alliance One International, Inc. Tobacco cultivar ‘AOB 175’
US7665472B2 (en) * 2007-11-06 2010-02-23 Alliance One International, Inc. Tobacco cultivar AOB 175 and products therefrom
WO2010046423A2 (en) 2008-10-22 2010-04-29 Basf Se Use of sulfonylurea herbicides on cultivated plants
WO2010046422A2 (en) 2008-10-22 2010-04-29 Basf Se Use of auxin type herbicides on cultivated plants
US20150250174A1 (en) 2012-10-01 2015-09-10 Basf Se Use of n-thio-anthranilamide compounds on cultivated plants
WO2014079820A1 (en) 2012-11-22 2014-05-30 Basf Se Use of anthranilamide compounds for reducing insect-vectored viral infections
CN103005703B (en) * 2012-12-12 2015-04-15 广东中烟工业有限责任公司 Cigarette designing method based on smoke perniciousness index
CN103005702B (en) * 2012-12-12 2015-03-18 广东中烟工业有限责任公司 Design method of less harmful cigarette based on harm index under deep smoking
CN102940310B (en) * 2012-12-12 2015-08-05 广东中烟工业有限责任公司 A kind of method of adjustment based on each component in the Cigarette design of N-nitrosamine burst size
EP3028573A1 (en) 2014-12-05 2016-06-08 Basf Se Use of a triazole fungicide on transgenic plants
WO2016091674A1 (en) 2014-12-12 2016-06-16 Basf Se Use of cyclaniliprole on cultivated plants
US11064696B2 (en) 2015-04-07 2021-07-20 Basf Agrochemical Products B.V. Use of an insecticidal carboxamide compound against pests on cultivated plants
EP3338552A1 (en) 2016-12-21 2018-06-27 Basf Se Use of a tetrazolinone fungicide on transgenic plants
WO2020003363A1 (en) * 2018-06-25 2020-01-02 学校法人近畿大学 Nutrition supplement or pharmaceutical composition for preventing deterioration in blood vessels due to the impact of ingesting nicotine
WO2021072288A1 (en) * 2019-10-10 2021-04-15 Altria Client Services Llc Compositions and methods based on qpt engineering for producing tobacco plants and products having altered alkaloid levels
CN113528537A (en) * 2021-08-11 2021-10-22 云南省烟草农业科学研究院 NtQPT2 gene mutant for reducing nicotine content in tobacco leaves and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005646A1 (en) * 1991-09-13 1993-04-01 Technology Management Services, S.A. Reduction of nicotine levels in tobacco
WO2000067558A1 (en) * 1999-05-06 2000-11-16 Michael Timko Regulation of gene expression in tobacco for manipulation of plant growth and secondary metabolism
WO2001059150A1 (en) * 2000-02-07 2001-08-16 Dos Remedios Cristobal Guiller Biomolecular toxicity assay
WO2002018607A2 (en) * 2000-08-30 2002-03-07 North Carolina State University Transgenic plants containing molecular decoys that alter protein content therein
EP1408780A2 (en) * 2000-11-10 2004-04-21 Vector Tobacco Ltd. Method and product for removing carcinogens from tobacco smoke
US20060157072A1 (en) * 2001-06-08 2006-07-20 Anthony Albino Method of reducing the harmful effects of orally or transdermally delivered nicotine
IL159213A0 (en) * 2001-06-08 2004-06-01 Vector Tobacco Ltd Modifying nicotine and nitrosamine levels in tobacco
AU2002340407A1 (en) * 2001-11-09 2003-05-26 Vector Tobacco Inc. Method and composition for mentholation of charcoal filtered cigarettes
EP1499188A4 (en) * 2002-04-09 2007-11-14 Vector Tobacco Ltd Tobacco having reduced nicotine and nitrosamines
US20050066986A1 (en) * 2003-09-30 2005-03-31 Nestor Timothy Brian Smokable rod for a cigarette

Also Published As

Publication number Publication date
EP1628681A4 (en) 2009-07-15
US20060237025A1 (en) 2006-10-26
EP1628681A1 (en) 2006-03-01
WO2005000352A1 (en) 2005-01-06
ZA200510170B (en) 2006-11-29
JP2007528204A (en) 2007-10-11
KR20060032141A (en) 2006-04-14
CN1812811A (en) 2006-08-02
AU2004251635A1 (en) 2005-01-06
CA2527648A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
AR044599A1 (en) METHOD FOR REDUCING THE HARMFUL EFFECTS OF NICOTINE ADMINISTERED BY ORAL OR TRANSDERMAL
Cogliano et al. Smokeless tobacco and tobacco-related nitrosamines
Silva Tobacco use and periodontal disease—the role of microvascular dysfunction
JP2017501714A (en) Liquid composition for electronic cigarette
AR060931A1 (en) PHARMACEUTICAL PRODUCT COVERED FOR INTRAORAL ADMINISTRATION OF NICOTINE AND ITS USE AND PREPARATION
DK1458252T3 (en) Tobacco and / or tobacco in combination with tobacco substitute composition for use as snus in the oral cavity
HUP0400161A2 (en) Modifying nicotine and nitrosamine levels in tobacco
BRPI0513917A (en) methods for forming a flavored filter for a smoking article, and for providing a flavored smoking article filter, smoking article, and, a smoking article filter
RU2014134073A (en) ORAL PRODUCT
BRPI0413733A (en) low exposure tobacco products
EA200301202A1 (en) HIDDEN TOBACCO PRODUCT
US9538782B2 (en) Inhibition of sensory irritation during consumption of smokeless tobacco products using a combinatorial approach
NO20084992L (en) Pharmaceutical product for intraoral delivery of nicotine including trometamol as a buffering agent
AR044383A1 (en) VARENICLINE PHARMACEUTICAL COMPOSITIONS
US20050034738A1 (en) Chewing tobacco substitute containing nicotine
BR112022023812A2 (en) TOBACCO-FREE ORAL NICOTINE POUCH COMPOSITION
KR102038342B1 (en) Nicotine formulation
KR101257828B1 (en) Composition of antismoking aid containing damascone
Sharma et al. Novel pathways and mechanisms of Nicotine-Induced oral carcinogenesis
US20060112965A1 (en) Chewing tobacco substitute containing cotinine
DE502004002023D1 (en) TOBACCO MIXING, AND A CIGARETTE CONTAINING THEREOF
Sintija et al. The oral microbiome of smokeless tobacco users in Latvia
FI127620B (en) Snuff-type composition of nicotine and crushed linseed
Ramachandran et al. Activation of platelets exposed to shear stress in the presence of smoke extracts of low-nicotine and zero-nicotine cigarettes: the protective effect of nicotine
Viegas Noncigarette forms of tobacco use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal